Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off

Eli Lilly's new weight-loss drug is creating so much buzz that Shenelle Rodriguez found a way to get ahold of the obesity treatment — even though it's not yet approved. And the hype around retatrutide has been promising for Eli Lilly stock.

Google, Broadcom Drive Delirious Demand. So Do 16 More Stocks.

Rocket Lab Breaks Out On Revenue Beat, Record Launch Contract

How Advanced Energy Plans To Unlock 'At Least Another Billion' In The AI Boom

How A Top-Performing Analyst-Driven Fund Beats The Market

Today's Spotlight

Experience 100+ new technical indicators and smarter charts––try it all for $24.95 ($125 off).

Subscribe >

Join IBD Live to watch and discuss the market action in real time with a team of top market analysts.

Subscribe >

Listen to IBD’s podcast for new investing tips and trade ideas every week!

Listen Now >

Investor's Business Daily - a Dow Jones affiliate

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.

Sent to: dupa@niepodam.pl

Investor's Business Daily, LLC, PO Box 300, Princeton, NJ 08543-0300

Need help? Have feedback? Feel free to contact us

Terms of Use | Privacy Notice | Manage Subscriptions | Unsubscribe

ID: 7133